Immunovia announces updated financial calendar
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Annual Report to be published | April 25, 2024 |
Q1 Report, 2024 | April 25, 2024 |
Annual General Meeting | June 4, 2024 |
Q2 Report, 2024 | August 22, 2024 |
Q3 Report, 2024 | November 14, 2024 |
For more information, please contact:
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
+46 709 11 56 08
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-announces-updated-financial-calendar,c3944595
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/immunovia-announces-updated-financial-calendar-302086865.html
SOURCE Immunovia AB